The positive side is RVNC will survive and Daxi will be available for both aesthetic and therapeutic patients. Daxi will provide superior outcomes to many patients which the #1 goal in our medical world. The Aesthetic World will see faster onset, longer duration, improved skin tone and better profitability.. The Therapeutic World will see faster onset, longer duration, less side effects from spread to the toxin and lower cost to the patient, provider and payer. These competitive advantages will be the factors and forces which grow Daxi sales.
The Negative side is Foley is and has to bring the "expense element" of RVNC in line with sales revenues. Aesthetic Daxi will continue to gain market share as the aesthetic team builds and converts injectors to Daxi with the benefits of Daxi and the additional profits that Daxi generates for the practice. Aesthetic injectors are all about profits. Therapeutic Daxi will soon be available and selling which will continue to build market presence. Therapeutic doctors are all about providing patients with the best medical product to treat the patient's condition. International Daxi sales will also begin. And there is also the Generic Botox element which is coming soon,
Foley had to and is cutting costs in anyway possible in an effort to match revenues and expenses to create a profitable RVNC. From the communications on this board it appears Foley is doing just that. Share price will recover and begin to go up as soon as investors realize and see how RNVC has been rebuilt. Foley is a hatchet man going into a company that was destine run out of cash and is now rebuilding the infra-structure to match sales and will come out a shining star.
